Tumor microenvironment in carcinomas recruits mesenchymal cells with an abnormal proangiogenic and invasive phenotype. It is not clear whether mesenchymal tumor cells (MTCs) derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several aspects the mesenchymal rearrangement which normally occurs during reparative processes such as wound healing. Mesenchymal stem cells (MSCs) play a crucial role in developmental and reparative processes and have extraordinary proangiogenic potential, on the basis of which they are thought to show great promise for the treatment of ischemic disorders. Here, we show that MTCs have proangiogenic potential and that they share the transcriptional expression of the best-known proangiogenic factors with MSCs. We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch. Our data (1) reveal crucial aspects of the proangiogenic phenotype of MTCs, (2) strongly suggest their stem origin and (3) signal the risk of therapeutic use of MSCs in tumorpromoting conditions.
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Introduction
The complex network of microenvironmental signals in carcinomas dramatically transforms the tumor mesenchymal compartment. The leading and most comprehensively studied effect is the recruitment of reactive stromal cells, which are crucial in supporting tumor growth via different pathways (Ronnov-Jessen et al., 1996) . The complete replacement of the epithelial parenchyma by mesenchymal tumor cells (MTCs) is a well-known occurrence in humans (Knutson et al., 2006) , in whom it constitutes a poor prognostic factor (Al Sayed et al., 2006) , as well as in experimental models of HER-2/neu tumors (De Wever and Mareel, 2003; Hill et al., 2005; Moody et al., 2005; Knutson et al., 2006) . Accordingly, we recently established a reactive stromal cell line, named A17, from a mammary carcinoma which spontaneously arose in HER-2/neu transgenic mice, and which is capable of generating mesenchymal tumors (Galie et al., 2005b) . It is not clear whether MTCs derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several ways the mesenchymal rearrangement which normally occurs during reparative processes, in line with Dvorak's definition of a tumor as 'a wound that does not heal' (Dvorak, 1986) . The role of mesenchymal stem cells (MSCs) in tissue homeostasis and repair is progressively emerging, and their possible manipulation is attracting increasing interest as a new frontier in therapeutic and reconstructive medicine. MSCs are pluripotent precursors initially identified in the bone marrow stroma and later found in other stromal districts, including the stromal vascular fraction (SVF) of adipose tissue (Zuk et al., 2002) .
The extraordinary proangiogenic potential is one of the most intriguing aspects that MTCs share with MSCs (Ronnov-Jessen et al., 1996) . Compared with normal fibroblasts (McAlhany et al., 2003) , MTCs have a dramatically enhanced capacity to promote angiogenesis (Orimo et al., 2005) , and play a determining role in supporting tumor growth with blood supply (Bhowmick et al., 2004) . Likewise, MSCs have exceptional proangiogenic potential, and are thought to have promise for the treatment of ischemic disease (Miranville et al., 2004; Planat-Benard et al., 2004; Cao et al., 2005) .
MTCs and MSCs belong to the same histogenetic lineage, exhibit similar morphological and immunophenotypical features, are involved in similar biological programs and share an extraordinary capability to generate new vessels. In the present study, we compared the proangiogenic phenotype and the stemness-related molecular signature of these two mesenchymal lineages, exploring the possibility that they have a common origin and represent the pathological and physiological expressions of the same differentiation potential. Furthermore, to investigate the local effects of MSCs in tumor progression, we monitored tumor growth and analysed the vascularization of transplanted HER-2/neu carcinomas with or without the co-injection of syngeneic MSCs.
Results
Carcinoma-derived mesenchymal tumors (A17 tumors) proved to be more vascularized than syngeneic carcinomas Previously, we showed that A17 tumors were much more vascularized than syngeneic epithelial tumors, both those which had spontaneously arisen in transgenic mice and those obtained by the subcutaneous injection of cancer cells, BB1, established from the same HER-2/ neu tumors (Galie et al., 2005a, b) . Here we confirmed a significant disparity between the vascular perfusion of A17 and BB1 tumors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with Gd-DTPA. Differences between A17 and spontaneous carcinomas were also confirmed, but did not prove statistically significant, probably because of the wide variability of spontaneous carcinomas (Figure 1 ; Table 1 ).
The CD31-specific immunohistochemical analysis showed that vessels in BB1 tumors mainly mapped within the stromal compartment, both in the peritumoral capsule and the intratumoral septa, and appeared large in size (Figure 2 ). The epithelial parenchyma contiguous to the peritumoral capsule proved to be more vascularized and to exhibit a higher cell density than the epithelial parenchyma in the center of the tumor and in areas distant from the stroma. In contrast, A17 vessels were distributed throughout the entire tumor section. On the basis of their size, comparable to that of single cells, and of their capillary distribution within the tumor parenchyma, A17 vessels appeared to form a complex systemic microcirculation. 
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This result indicated that the epithelial compartment in carcinomas is completely dependent on stromal cells for blood supply, while the mesenchymal cell populations of tumors were capable of independent neoangiogenesis.
Several proangiogenic genes are overexpressed in carcinoma-derived mesenchymal tumors compared with syngeneic carcinomas To investigate the molecular bases of the extraordinary proangiogenic potential of carcinoma-derived mesenchymal tumors, we analysed the transcriptional profile of their angiogenesis-related genes (Figure 3) .
The list of genes which were overexpressed in A17 as compared to BB1 and Spontaneous tumors (Table 2;  Supplementary Table) included potent proangiogenic factors like hepatocyte growth factor (HGF), cyclooxygenase-2 (COX-2), insulin-like growth factor (IGF-1), angiopoietins 1 and 2, platelet-derived growth factor-a (PDGF-a), transforming growth factor-b1 (Tgfb1) and connective tissue growth factor (CTGF).
With the exception of ErbB2, none of the genes proved to be significantly overexpressed (more than 2-fold) in BB1 or Spontaneous tumors compared to A17 tumors.
Platelet endothelial cell adhesion molecule-1 (PE-CAM-1 or CD31) and VE-cadherin, both of which are markers specific for endothelial cells, proved to be moderately or notably overexpressed in A17 tumors (0.45 and 0.65, respectively) compared with BB1 (0.27 and 0.23) and Spontaneous tumors (0.30 and 0.19), thus confirming the differences in their vascular architecture. Vascular endothelial growth factor-a (VEGF-A) showed a moderate and similar expression in all of the tumor lineages.
MTCs phenotype correlated with MSCs phenotype
Since A17 cells and tumors share surprising proangiogenic potential, as well as histogenetic origin, with MSCs, we were interested in comparing the angiogenesis-related transcriptional phenotype of these two mesenchymal lineages (Figure 3 ; Supplementary Table) . Figure 2 Anti-CD31 immunostaining of BB1 and A17 tumor sections revealed a different architecture of blood vessels. In BB1 parenchyma (a-c), blood vessels appeared large in size and restricted to intratumoral stromal septa. In A17, vessels (d-f) were smaller in size and homogeneously distributed in the parenchyma.
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The mean expression values proved to be higher in MSCs, both at VII (0.406) and XVII (0.490) passages, in A17 tumors (0.438) and, to a lesser extent, in A17 cells (0.365) than in BB1 cells (0.328), BB1 tumors (0.299) or Spontaneous tumors (0.264).
We then quantified the similarities between the profiles of the lineages on the basis of the correlation index (C i ) (Figure 3c ; Table 3 ). As expected, the highest C i values resulted from the comparison between the two lineages of MSCs (respectively cultured up to VII and XVII passages, Interestingly, we found very few genes displaying a significant (>2-fold) difference in expression between the two lineages (Table 4) .
Cytofluorimetric analysis confirmed a similar cell surface immunophenotype in A17 cells and MSCs for molecules included in the marker panel commonly used for MSC identification (Table 5 ). The only difference we found was VCAM-1/CD106, which was expressed by MSCs but not by A17 cells.
Mesenchymal stem cells favor tumor onset
To investigate the capability of MSCs to favor tumor growth and vasculogenesis we subcutaneously coimplanted BB1 cells with syngeneic MSCs on the backs of FVB mice. Co-injection of BB1 and FVB/MSCs determined earlier onset of the tumors than injection of BB1 alone (Figure 5a ), suggesting a decisive role of MSCs in prompting the angiogenic switch. However, after their onset, tumors grew with a comparable kinetic (Figure 5b) , and Gd-DTPA DCE-MRI did not show significant differences in vascularization between BB1 (n ¼ 4, 1.63 Â 10 6 ) and BB1 þ ADAS (n ¼ 4, 1.50 Â 10 6 ).
Discussion
During tumor growth, a complex network of microenvironmental signals generates mesenchymal populations whose capability to provide mitogenic stimuli (Hayward et al., 2001 ) and blood supply (Orimo et al., 2005) is strongly enhanced if compared with that of normal fibroblasts. These aberrant MTCs not only support the neoplastic epithelial growth of the epithelial compartment, but can also follow an autonomous pathogenetic fate, developing into rapidly growing, highly vascularized and invasive mesenchymal tumors. However, the target of this 'mesenchymal activation' remains unclear. Some authors think that MTCs come directly from cancer cells as a consequence of epithelialmesenchymal transition (Petersen et al., 2001; Pennacchietti et al., 2003; Knutson et al., 2006; Thiery and Sleeman, 2006 ). An alternative explanation is that MTCs derive from preexisting stromal fibroblasts or their precursors, following microenvironmentally induced 'epigenetic changes' (Kurose et al., 2002; Hu et al., 2005; Fiegl et al., 2006) . Our results show functional and molecular analogies between MTCs and MSCs. We demonstrated that MTSs as well as MSCs exhibit extraordinary proangiogenic potential. A17 and MSC profiles shared the expression of molecules that are known to be potent proangiogenic factors, such as angiopoietins, HGF (only A17 tumors), COX-2, IGF-1, PDGF-a, VEGF-A, VEGF-B, VEGF-C and TGF-b1. The expression pattern of CTGF is of particular interest. A constitutive expression of CTGF has recently been found to discriminate reactive from normal stromal cells, and it has been shown that this molecule strongly promotes angiogenesis in prostate cancer . We found a moderate expression of CTGF in BB1 and spontaneous carcinomas, probably due to the reactive stromal component of these carcinomas, but not in BB1 cells. A basal expression of this gene was found in A17 cells, while in A17 tumors and MSC lineages the expression was similar and very great. These results highlight a pathway common to reactive stromal cells and MSCs. We also showed the identical molecular signature of stemness-related genes in A17 cells and MSCs. Only six genes showed significantly different expression. Among these, we considered noteworthy cytokeratin 14, which proved to be expressed in A17 but not in MSCs, patched homolog 1, which was highly expressed in A17 but not expressed in MSCs, and tenascin C, which was not expressed in A17 but was expressed in MSCs. Cytokeratin 14 is a marker of myoepithelial lineage and its surface expression by A17 cells has already been described (Galie et al., 2005b) . Cytofluorimetric analysis confirmed the analogy between A17 and MSC immunophenotype for most of the genes analysed.
MTCs and MSCs displayed similar molecular signatures and proangiogenic phenotypes. The analogy could be thought of as due to an epigenetic phenotypical convergence. Alternatively, it might suggest that MSCs are direct precursors of MTCs. The absence of CD106 (VCAM-1) expression by A17 cells appears inconsistent with this conclusion. However, microarray analysis and reverse transcription (RT)-PCR demonstrated a transcriptional expression of CD106 in A17 as well as in Figure 4 Stemness-related gene arrays of A17 cells and mesenchymal stem cells (MSCs). The images were generated by reproducing in grayscale the values obtained by the densitometric analysis of the arrays. The MSC array was generated using the mean values of arrays of three MSC lineages cultured for different periods (0 passage, VII passage and XVII passage). The table indicates the genes included in the analysis and their respective position in the array. The upper and the lower bars of the scatterplot indicate the threshold of 2-fold overexpression and underexpression, respectively, of MSC genes with respect to A17 genes. Most genes did not prove more than 2-fold over-or underexpressed in the comparison between the two cell lineages.
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MSCs, suggesting a posttranscriptional downregulation of this molecule as a result of transformation-associated 'epigenetic change'. Notably, we found CD34 transcript both in A17 and MSC lineages using microarray analysis and RT-PCR. As expected, the CD34 protein was not detected by cytofluorimetric analysis. CD34 downregulation in MSCs as well as in MTCs could be the result of in vitro culture artifacts, as uncultured SVF and primary culture (within 3 days) of adipose-derived MSCs are CD34 positive (Miranville et al., 2004; PlanatBenard et al., 2004) .
Along with molecular signature, we also found a functional analogy between MTCs and MSCs, which when co-injected with cancer cells into syngeneic mice MSCs determined earlier tumor appearance. However, after their onset, tumors grew with a comparable kinetic and did not show significant differences in vascularization. These results suggest that MSCs injected together with cancer cells play a decisive role in prompting the angiogenic switch (Folkman et al., 1989; Holmgren et al., 1995; Naumov et al., 2006) , which is known to be necessary in the early phase of tumor development, for tumor mass to expand beyond the initial microscopic size. This process is closely dependent on the recruitment of endothelial cell precursors and the formation of new capillaries that converge toward the tumor. It is plausible that paracrine release of potent proangiogenic factors by locally injected MSCs accelerates the angiogenic switch. However, the physical recruitment of MSCs into the tumor stroma or their possible direct differentiation to endothelial cells needs to be investigated. We speculate that the delay in tumor onset in mice injected with BB1 alone is due to the time needed for recruitment of endogenous reactive stromal cells (perhaps endogenous MSCs), which are required for the angiogenic switch. However, after their initial onset, both BB1 and BB1 þ MSCs have analogous angiogenic machinery. We speculate this machinery to have an endogenous origin for BB1 tumors and an exogenous origin for BB1 þ MSCs tumors.
Our results are consistent with the theory of the stem origin of tumors, which is currently the subject of increasing interest in cancer research (Reya et al., 2001; Dingli and Michor, 2006) . Evidence which has emerged in recent years suggests that initiation, development and homeostasis of tumors is determined by a small subset of cells with stem properties, termed cancer stem cells (Keith, 2004) . These cells originate through genetic and/ or epigenetic alterations of stem precursors 'locked' in an aberrant undifferentiated status, characterized by an enhanced proliferation rate, defects in phenotypic plasticity, loss of differentiation potential and weak responsiveness to microenvironmental control (Feinberg, 2007) . The existence of cancer stem cells has been proven for many types of tumors (Lapidot et al., 1994; Bonnet and Dick, 1997; Al Hajj et al., 2003; Galli et al., 2004; Singh et al., 2004; Ponti et al., 2005; Li et al., 2007) . In the context of carcinomas, most studies have aimed to identify and characterize the precursors of epithelial tumor cells, which are commonly thought to trigger carcinogenesis (Shipitsin et al., 2007) . However, the recently reported propensity of MSCs to spontaneous transformation (Burns et al., 2005; Rubio et al., 2005) raises the question whether the reactive stromal cells of carcinomas might have a stem origin too. MSCs are by definition the precursors of fibroblasts. Their contribution to generating tumor stroma (Hung et al., 2005; Wolf et al., 2005) , especially its reactive subpopulations (Direkze et al., 2004) , has already been suggested; so they could be candidates for the tumorpromoting or tumorigenic phenotypical changes that a neoplastic microenvironment induces in the stromal population.
Given the phenotypical similarity between MSCs and MTCs, the comparative characterization of their molecular repertoire and their effects in a tumor microenvironment is doubly informative, as it contributes to understanding the molecular basis of (1) the beneficial effects of MSCs and (2) the aberrant potential of MTCs. 
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Materials and methods
Cell and animal models Spontaneous tumors were mammary carcinomas that arose in FVB mice, line 233, transgenic for the activated isoform of rat HER-2/neu (NeuNT) oncogene (FVB/neuT233), and were purchased from Charles River Laboratories (Calco, Italy). A17 ( Figure 6a ) and BB1 cell lines were established from spontaneous HER-2/neu transgenic tumors as previously described (Galie et al., 2005b) . For more details see Supplementary Materials. (Figure 6b ) were isolated from inguinal adipose tissues of three different FVB mice using standard protocols (Zuk et al., 2002; Rigotti et al., 2007) . Briefly, SVF was obtained after collagenase digestion and seeded in culture. After 72 h, nonadherent cells were removed. When they were 70-80% confluent, adherent cells were expanded. After 1-2 weeks of culture a homogeneous cell population was obtained. These cells were identified as MSCs on the basis of their immunophenotype profile and their multilineage plasticity (Supplementary Data), as previously described Rigotti et al., 2007) . Specifically, the positivity of CD106 (VCAM-1), CD73, CD29, CD44, CD90 and the lack of hematopoietic (anti-CD45, -CD14, -CD11c, CD123 and -CD34 monoclonal antibodies) and endothelial cell markers (with anti-CD31 monoclonal antibody) were assessed by means of cytofluorimetric analysis. Multilineage differentiation potential was assessed by testing the ability of cells to differentiate into adipocytes, osteoblasts and chondrocytes. For more detail see Supplementary Materials.
Mesenchymal stem cells MSCs

DCE-MRI
Dynamic image acquisition Functional parameters of the blood architecture of A17 and syngeneic epithelial tumors (BB1 and Spontaneous) were assessed using DCE-MRI with Gd-DTPA as contrast agent. For more details see Supplementary Materials.
Microarray-based transcriptional analysis Microarray procedure All the steps of microarray procedure were carried out using reagents from Superarray Bioscience Corporation (Frederick, MD, USA) and closely following the Data analysis Data from arrays were analysed using GEArray Expression Analysis Suite (Superarray Bioscience Corporation). Quantitative values of expression were corrected to the background, normalized with respect to the positive control genes included in the arrays and reported as ratios to the mean values of normalization genes.
Genes with values o0.25 were considered to be 'not expressed'; genes with values X0.25 but p0.60 were considered 'expressed'; genes with values X0.60 were considered 'highly expressed'.
Differences of expression of twofold or more between the lineages under analysis were considered significant.
Clustering of lineage profiles
To perform statistical analysis we clustered the samples as: A17 profile (A17 cells and A17 tumors), MSC profile (MSCs at VII and MSCs at XVII passage), epithelial profile (BB1 cells, BB1 tumors, Spontaneous tumors).
ANOVA analysis was used to assess the statistical significance of the differences between C i of the various lineage profiles. 
RT-PCR
Immunohistochemistry
For CD-31 immunostaining, tumors were fixed overnight in zinc fixative. Endothelial cells were identified by immunohistochemical staining for PECAM-1 or CD31, using a rat monoclonal antibody directed against mouse CD31 (Pharmingen, San Diego, CA, USA). For more details see Supplementary Materials.
